Affordable Access

deepdyve-link
Publisher Website

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Authors
  • Conte, PierFranco1
  • Schneeweiss, Andreas2
  • Loibl, Sibylle3, 4
  • Mamounas, Eleftherios P.5
  • von Minckwitz, Gunter3
  • Mano, Max S.6
  • Untch, Michael7
  • Huang, Chiun‐Sheng8
  • Wolmark, Norman9
  • Rastogi, Priya9
  • D’Hondt, Veronique10
  • Redondo, Andrés11
  • Stamatovic, Ljiljana12
  • Bonnefoi, Hervé13
  • Castro‐Salguero, Hugo14
  • Fischer, Hans H.15
  • Wahl, Tanya16
  • Song, Chunyan17
  • Boulet, Thomas18
  • Trask, Peter17
  • And 1 more
  • 1 IRCCS, Italy , (Italy)
  • 2 National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany , (Germany)
  • 3 GBG, Germany , (Germany)
  • 4 Centre for Haematology and Oncology Bethanien, Germany , (Germany)
  • 5 NSABP Foundation and Orlando Health University of Florida Health Cancer Center
  • 6 Instituto do Câncer do Estado de São Paulo, Brazil , (Brazil)
  • 7 AGO‐B and HELIOS Klinikum Berlin Buch, Germany , (Germany)
  • 8 National Taiwan University Hospital and National Taiwan University College of Medicine, Taiwan , (Taiwan)
  • 9 NSABP Foundation and University of Pittsburgh
  • 10 Institut Régional du Cancer de Montpellier, France , (France)
  • 11 Hospital Universitario La Paz–IdiPAZ, Spain , (Spain)
  • 12 Institute for Oncology and Radiology of Serbia, Serbia , (Serbia)
  • 13 Institut Bergonié Unicancer and Bordeaux University, France , (France)
  • 14 Grupo Medico Angeles, Guatemala , (Guatemala)
  • 15 GBG and Evangelische Kliniken Gelsenkirchen, Germany , (Germany)
  • 16 Swedish Cancer Institute
  • 17 Genentech, Inc.
  • 18 F. Hoffmann‐La Roche, Switzerland , (Switzerland)
  • 19 NSABP Foundation and Houston Methodist Cancer Center
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Apr 14, 2020
Volume
126
Issue
13
Pages
3132–3139
Identifiers
DOI: 10.1002/cncr.32873
PMID: 32286687
PMCID: PMC7317721
Source
PubMed Central
Keywords
License
Unknown
External links

Abstract

Patient‐reported outcomes are reported from the randomized, phase 3 KATHERINE trial, which demonstrated significantly improved invasive disease–free survival with adjuvant T‐DM1 compared with trastuzumab in patients who had residual invasive disease following neoadjuvant chemotherapy plus HER2‐targeted therapy. Patients who are treated with T‐DM1 have a greater incidence of any grade and grade ≥3 adverse events compared with trastuzumab‐treated patients; however, these adverse events appear to have a minimal impact on patient‐reported quality of life.

Report this publication

Statistics

Seen <100 times